ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

NCT02874651 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Unacceptable toxicity (nasopharynx necrosis and massive hemorrhage)

Conditions

Nasopharyngeal Neoplasms

Interventions

DRUG: Apatinib
DRUG: Placebo

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]